Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Biotech
AnaptysBio abandons rosnilimab for UC after phase 2 fail
AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis after the PD-1 agonist flunked a phase 2 study.
James Waldron
Nov 10, 2025 10:05am
Odyssey saga continues with $213M series D
Sep 10, 2025 8:00am
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Aug 13, 2025 1:48pm
AbbVie ends development of IL-1 asset in ulcerative colitis
Jul 31, 2025 12:32pm
Abivax aces phase 3 colitis trials as end of cash runway looms
Jul 23, 2025 6:30am
Sanofi shows how $500M IBD bet compares to Merck, Roche rivals
Feb 24, 2025 8:11am
